Valeant Pharmaceuticals International, Inc. Form 3 August 24, 2016 FORM 3 UNITED STATES SEC

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Herendeen Paul			2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name <b>and</b> Ticker or Trading Symbol Valeant Pharmaceuticals International, Inc. [VRX]					
(Last)	(First)	(Middle)	08/22/2016	4. Relationship of Reporting Person(s) to Issuer			5. If Amendment, Date Original Filed(Month/Day/Year)		
400 SOMER	RSET COR	PORATE							
BOULEVA	RD			(Check all applicable)					
(Street) BRIDGEWATER, NJ 08807			Director 10% Owner X Officer Other (give title below) (specify below) EVP, Chief Financial Officer		ow)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table I - N	I - Non-Derivative Securities Beneficially Owned					
1.Title of Secur (Instr. 4)	rity		2. Amount of Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owner (Instr.	*		
Reminder: Report on a separate line for each class of securities benef owned directly or indirectly. Persons who respond to the collection of			5 5	EC 1473 (7-02	)				
information contained in this form are not required to respond unless the form displays a currently valid OMB control number.									

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I)	

OMB APPROVAL

Estimated average burden hours per

3235-0104

January 31,

2005

0.5

OMB

Number:

Expires:

response...

(Instr. 5)

# **Reporting Owners**

Reporting Owner Na	Relationships					
· · · · · · · · · · · · · · · · · · ·	Director	10% Owner	Officer	Other		
Herendeen Paul 400 SOMERSET CORPORAT BRIDGEWATER, NJ 0880		Â	Â	EVP, Chief Financial Officer	Â	
Signatures						
Kelly Webber for Paul Herendeen	08/24/2016					
**Signature of Reporting Person	Date					
Evelopetion of De						

## **Explanation of Responses:**

### No securities are beneficially owned

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.